New cancer drug candidate T-1101 enters first human tests
NCT ID NCT04685473
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This early-stage trial tests a new oral drug called T-1101 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and understand how the body processes the drug. Researchers will also look for early signs of tumor shrinkage. The study involves about 24 participants and lasts at least 28 days per person.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- T-1101 (Tosylate)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 24 participants, so the drug may prove too toxic or ineffective. It is not yet known if T-1101 will work in humans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
-
National Cheng Kung University Hospital
Tainan, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.